A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Versus Observation as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection
A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Versus Observation as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection
This Phase III, open-label, randomized, multicenter study is to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with observation in participants with muscle-invasive UC who are at high risk for recurrence following resection. Eligible participants were randomized by a 1:1 ratio into atezolizumab group or control group.
Inclusion Criteria:
Exclusion Criteria:
Scottsdale, Arizona 85258, United States
Iowa City, Iowa 52242, United States
Shanghai, 200092, China
Bochum, 44791, Germany
Herne, 44625, Germany
Mannheim, 68167, Germany
Hafia, 3109601, Israel
Naples, Campania 80131, Italy
Bologna, Emilia-Romagna 40138, Italy
Meldola, Emilia-Romagna 47014, Italy
Ehime, 791-0280, Japan
Hokkaido, 003-0804, Japan
Późna, 60-569, Poland
Toru?, 87-100, Poland
Wroclaw, 50-556, Poland
Moscow, Moscow Oblast 125248, Russia
Yekaterinburg, Sverdlovsk Oblast 620905, Russia
Zurich, 8091, Switzerland
Adana, 01230, Turkey (Türkiye)
Edirne, 22770, Turkey (Türkiye)
Kar??yaka, 35575, Turkey (Türkiye)
Kharkiv, Kharkiv Governorate 61037, Ukraine